Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of St Jude Medical Inc (NYSE: STJ) acted responsibly on behalf of investors’ profitability in the planned $25 billion sale to Abbott Laboratories (NYSE: ABT).

On April 28, 2016, St Jude Medical Inc (NYSE: STJ) and Abbott Laboratories (NYSE: ABT) announced that they had entered into a merger agreement. Under the terms of the agreement, shareholders of St Jude Medical will receive $46.75 in cash and 0.8708 shares of Abbott common stock for each share of St Jude Medical they own.

Based in St Paul, Minnesota, and founded in 1976 St Jude Medical Inc develops, manufactures, and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular and atrial fibrillation therapy.

The investigation is looking to uncover whether St Jude Medical Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $82.50 per share.

If you purchased St Jude Medical Inc (NYSE: STJ) prior to April 28, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185